RAC is definitely flying under the radar. I have been following this one quite a while and its only a matter of time before this is P3 ready. With plenty of safety studies conducted in the 80s there is obviously ample safety data for the FDA to allow p3 to proceed. While efficacy measures would have changed since then this is still very much undervalued.
There wouldn’t be many sub 10 mill EV oncology plays that are phase 3 ready.
All this needs for a massive rerate is some movement on the NPP front and FDA clearance and this will fly.
The recent appointment of Tom Lee tells me things will start to heat up very soon. His resume is quite impressive.
Ann: June 2018 Quarterly Report, page-7
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |